Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Chronic
Inflammatory Demyelinating Polyneuropathy (CIDP) – Pipeline Review, H1
2019” drug pipelines has been added to ResearchAndMarkets.com’s
offering.

Chronic Inflammatory Demyelinating Polyneuropathy – Pipeline Review, H1
2019, provides comprehensive information on the therapeutics under
development for Chronic Inflammatory Demyelinating Polyneuropathy
(Central Nervous System), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.

The Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous
System) pipeline guide also reviews of key players involved in
therapeutic development for Chronic Inflammatory Demyelinating
Polyneuropathy (CIDP) and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies
/Universities /Institutes, the molecules developed by Companies in
Pre-Registration, Phase III, Phase I and Preclinical stages are 2, 3, 4
and 2 respectively.

Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous
System) pipeline guide helps in identifying and tracking emerging
players in the market and their portfolios, enhances decision making
capabilities and helps to create effective counter strategies to gain
competitive advantage.

Scope:

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Chronic Inflammatory Demyelinating Polyneuropathy
  (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Chronic
  Inflammatory Demyelinating Polyneuropathy (Central Nervous System) by
  companies and universities/research institutes based on information
  derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Chronic
  Inflammatory Demyelinating Polyneuropathy (Central Nervous System)
  therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Chronic Inflammatory Demyelinating
  Polyneuropathy (Central Nervous System) therapeutics based on
  mechanism of action (MoA), drug target, route of administration (RoA)
  and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy
  (Central Nervous System)

Reasons to buy:

• Procure strategically important competitor information, analysis, and
  insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio
  and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under
  development for Chronic Inflammatory Demyelinating Polyneuropathy
  (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of
  leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players
  and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding
  Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous
  System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by
  identifying prospective partners with the most attractive projects to
  enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects
  and understand from the know-how what drove them from pipeline.

Companies Mentioned

• Argenx SE
• CSL Ltd
• GeNeuro SA
• Immupharma Plc
• Momenta Pharmaceuticals Inc
• Octapharma AG
• Pfizer Inc
• Takeda Pharmaceutical Co Ltd
• Teijin Pharma Ltd
• UCB SA

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/997jz9/chronic?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs